Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Hypertension

Hope for resistant hypertension through BrigHTN and PRECISION

Nature Reviews Nephrology volume 19, pages 216–217 (2023)Cite this article

Subjects

An estimated 10–15% of individuals with hypertension are resistant to available antihypertensive therapies. Findings from two new clinical trials — BrigHTN and PRECISION — that assessed the blood pressure-lowering effects of the aldosterone synthase inhibitor baxdrostat and the dual endothelin receptor antagonist aprocitentan, respectively, suggest these approaches hold promise for patients with treatment-resistant hypertension.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Beneficial effects of aldosterone synthase inhibition by baxdrostat and blockade of endothelin A and B receptors by aprocitentan.

References

  1. Chobanian, A. V. Shattuck Lecture. The hypertension paradox — more uncontrolled disease despite improved therapy. N. Engl. J. Med. 361, 878–887 (2009).

    Article  CAS  PubMed  Google Scholar 

  2. Carey, R. M. et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 72, e53–e90 (2018).

    Article  CAS  PubMed  Google Scholar 

  3. Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2213169 (2022).

    Article  PubMed  Google Scholar 

  4. Schlaich, M. P. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400, 1927–1937 (2022).

    Article  CAS  PubMed  Google Scholar 

  5. Acelajado, M. C., Hughes, Z. H., Oparil, S. & Calhoun, D. A. Treatment of resistant and refractory hypertension. Circ. Res. 124, 1061–1070 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Williams, B. et al. British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059–2068 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lenzini, L., Zanotti, G., Bonchio, M. & Rossi, G. P. Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data. Pharmacol. Res. 163, 105332 (2021).

    Article  CAS  PubMed  Google Scholar 

  8. Clozel, M. Aprocitentan and the endothelin system in resistant hypertension. Can. J. Physiol. Pharmacol. 100, 573–583 (2022).

    Article  CAS  PubMed  Google Scholar 

  9. Elijovich, F., Laffer, C. L., Schiffrin, E. L., Gavras, H. & Amador, E. Endothelin-aldosterone interaction and proteinuria in low-renin hypertension. J. Hypertens. 22, 573–582 (2004).

    Article  CAS  PubMed  Google Scholar 

  10. Manosroi, W. & Williams, G. H. Genetics of human primary hypertension: focus on hormonal mechanisms. Endocr. Rev. 40, 825–856 (2019).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Institute of the McGill University Health Centre (RI-MUHC), Department of Medicine and Department of Family Medicine, McGill University, Montreal, Quebec, Canada

    R. M. Touyz

  2. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    D. G. Harrison

  3. Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA

    D. G. Harrison

  4. Department of Physiology, Vanderbilt University Medical Center, Nashville, TN, USA

    D. G. Harrison

  5. Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA

    D. G. Harrison

Authors
  1. R. M. Touyz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. G. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. M. Touyz.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Touyz, R.M., Harrison, D.G. Hope for resistant hypertension through BrigHTN and PRECISION. Nat Rev Nephrol 19, 216–217 (2023). https://doi.org/10.1038/s41581-023-00676-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-023-00676-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing